Michael Philip Barnes
Research Subjects
Michael Philip Barnes has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Price
Population Health Sciences Institute, Newcastle University, United Kingdom (C.P.).
2 shared publications - Gary A. Ford
Institute for Ageing and Health (Stroke Research Group), Newcastle University, Newcastle Upon Tyne, UK
2 shared publications - Helen Rodgers
Institute for Ageing and Health (Stroke Research Group), Newcastle University, Newcastle Upon Tyne, UK
2 shared publications - Laura A. Graham
International Centre for Neurorehabilitation, Walkergate Park, Benfield Road, Newcastle upon Tyne NE6 4QD, UK
2 shared publications - Lisa Shaw
Population Health Sciences Institute, Newcastle University
2 shared publications - Nick Steen
Institute of Health and Society, Newcastle University, Baddiley-Clark Building, Richardson Road, Newcastle upon Tyne, NE2 4AX, UK
2 shared publications
Latest Publications
The case for medical cannabis—an essay by M P Barnes
Legal restrictions on the grounds that cannabis has no therapeutic use have impeded research, says M P Barnes, but evidence shows cannabinoids may have benefit in several indications, calling for doctors to be allowed to prescribe the drug as they can in many other countries
The case for medical cannabis—an essay by M P Barnes
Legal restrictions on the grounds that cannabis has no therapeutic use have impeded research, says M P Barnes, but evidence shows cannabinoids may have benefit in several indications, calling for doctors to be allowed to prescribe the drug as they can in many other countries
- Open Access
- 1 January 2018
- Published by Whitehouse Publishing in Advances in Clinical Neuroscience & Rehabilitation
Medical cannabis – time for change
The barriers to use cannabis are breaking down and over 40 countries have legalised the plant for medicinal use.
- 1 January 2018
- Published by Whitehouse Publishing in Advances in Clinical Neuroscience & Rehabilitation
Open AccessMedical cannabis – time for change
The barriers to use cannabis are breaking down and over 40 countries have legalised the plant for medicinal use.
- Open Access
- 3 July 2016
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 39 (14) , 1428-1434
An international survey of patients living with spasticity
Purpose: To better understand patient perspectives on the life impact of spasticity. Methods: Global Internet survey (April 2014–May 2015) of 281 people living with spasticity. Results: Respondents indicated that spasticity has a broad impact on their daily-life: 72% reported impact on quality of life, 44% reported loss of independence and 44% reported depression. Most respondents (64%) were cared for by family members, of whom half had stopped working or reduced their hours. Overall, 45% reported dissatisfaction with the information provided at diagnosis; main reasons were “not enough information” (67%) and “technical terminology” (36%). Respondents had high treatment expectations; 63% expected to be free of muscle spasm, 41% to take care of themselves and 36% to return to a normal routine. However, 33% of respondents had not discussed these expectations with their physician. The most common treatments were physiotherapy (75%), botulinum neurotoxin (BoNT, 73%) and oral spasmolytics (57%). Of those treated with BoNT, 47% waited >1 year from spasticity onset to treatment. Conclusions: This survey emphasises the broad impact of spasticity and highlights unmet needs in the patient journey. Improvements with regards to communication and the therapeutic relationship would be especially welcomed by patients, and would help manage treatment expectations.
- 3 July 2016
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 39 (14) , 1428-1434
Open AccessAn international survey of patients living with spasticity
Purpose: To better understand patient perspectives on the life impact of spasticity. Methods: Global Internet survey (April 2014–May 2015) of 281 people living with spasticity. Results: Respondents indicated that spasticity has a broad impact on their daily-life: 72% reported impact on quality of life, 44% reported loss of independence and 44% reported depression. Most respondents (64%) were cared for by family members, of whom half had stopped working or reduced their hours. Overall, 45% reported dissatisfaction with the information provided at diagnosis; main reasons were “not enough information” (67%) and “technical terminology” (36%). Respondents had high treatment expectations; 63% expected to be free of muscle spasm, 41% to take care of themselves and 36% to return to a normal routine. However, 33% of respondents had not discussed these expectations with their physician. The most common treatments were physiotherapy (75%), botulinum neurotoxin (BoNT, 73%) and oral spasmolytics (57%). Of those treated with BoNT, 47% waited >1 year from spasticity onset to treatment. Conclusions: This survey emphasises the broad impact of spasticity and highlights unmet needs in the patient journey. Improvements with regards to communication and the therapeutic relationship would be especially welcomed by patients, and would help manage treatment expectations.
- Open Access
Cost-Effectiveness of Treating Upper Limb Spasticity Due to Stroke with Botulinum Toxin Type A: Results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial
Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources. This study compared the cost-effectiveness of treating post-stroke upper limb spasticity with botulinum toxin type A plus an upper limb therapy programme against the therapy programme alone. Data on resource use and health outcomes were prospectively collected for 333 patients with post-stroke upper limb spasticity taking part in a randomized trial and combined to estimate the incremental cost per quality adjusted life year (QALY) gained of botulinum toxin type A plus therapy relative to therapy alone. The base case incremental cost-effectiveness ratio (ICER) of botulinum toxin type A plus therapy was £93,500 per QALY gained. The probability of botulinum toxin type A plus therapy being cost-effective at the England and Wales cost-effectiveness threshold value of £20,000 per QALY was 0.36. The point estimates of the ICER remained above £20,000 per QALY for a range of sensitivity analyses, and the probability of botulinum toxin type A plus therapy being cost-effective at the threshold value did not exceed 0.39, regardless of the assumptions made.
Open AccessCost-Effectiveness of Treating Upper Limb Spasticity Due to Stroke with Botulinum Toxin Type A: Results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial
Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources. This study compared the cost-effectiveness of treating post-stroke upper limb spasticity with botulinum toxin type A plus an upper limb therapy programme against the therapy programme alone. Data on resource use and health outcomes were prospectively collected for 333 patients with post-stroke upper limb spasticity taking part in a randomized trial and combined to estimate the incremental cost per quality adjusted life year (QALY) gained of botulinum toxin type A plus therapy relative to therapy alone. The base case incremental cost-effectiveness ratio (ICER) of botulinum toxin type A plus therapy was £93,500 per QALY gained. The probability of botulinum toxin type A plus therapy being cost-effective at the England and Wales cost-effectiveness threshold value of £20,000 per QALY was 0.36. The point estimates of the ICER remained above £20,000 per QALY for a range of sensitivity analyses, and the probability of botulinum toxin type A plus therapy being cost-effective at the threshold value did not exceed 0.39, regardless of the assumptions made.
- 26 April 2010
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 122 (4) , 295-302
Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study
To assess efficacy and safety of two dilutions of botulinum neurotoxin type A NT 201 (Xeomin®) in patients with upper limb spasticity of diverse etiology. Changes in functional disability and muscle tone from baseline to week 4 after NT 201 treatment. One hundred ninety-two patients with stroke, brain injury, multiple sclerosis, or cerebral palsy were randomized to either 50 or 20 U/ml NT 201 dilutions. The maximum total NT 201 dose was 495 units. Four weeks post-injection, a ≥ 1-point reduction was observed on the Disability Assessment Scale in 57.1%, and on the Ashworth scale in ≥ 62.2% of patients. The 20 U/ml NT 201 dilution was non-inferior to the 50 U/ml NT 201 dilution. Global improvement was rated high by patients (80.2%) and investigators (89.0%). NT 201 improved functional disability and muscle tone and was well tolerated in patients with upper limb spasticity of diverse etiology in both dilutions.
- 26 April 2010
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 122 (4) , 295-302
Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study
To assess efficacy and safety of two dilutions of botulinum neurotoxin type A NT 201 (Xeomin®) in patients with upper limb spasticity of diverse etiology. Changes in functional disability and muscle tone from baseline to week 4 after NT 201 treatment. One hundred ninety-two patients with stroke, brain injury, multiple sclerosis, or cerebral palsy were randomized to either 50 or 20 U/ml NT 201 dilutions. The maximum total NT 201 dose was 495 units. Four weeks post-injection, a ≥ 1-point reduction was observed on the Disability Assessment Scale in 57.1%, and on the Ashworth scale in ≥ 62.2% of patients. The 20 U/ml NT 201 dilution was non-inferior to the 50 U/ml NT 201 dilution. Global improvement was rated high by patients (80.2%) and investigators (89.0%). NT 201 improved functional disability and muscle tone and was well tolerated in patients with upper limb spasticity of diverse etiology in both dilutions.
- Open Access
- 23 October 2008
- Published by Springer Nature in Trials
- Vol. 9 (1) , 59
Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A
Following a stroke, 55–75% of patients experience upper limb problems in the longer term. Upper limb spasticity may cause pain, deformity and reduced function, affecting mood and independence. Botulinum toxin is used increasingly to treat focal spasticity, but its impact on upper limb function after stroke is unclear. The aim of this study is to evaluate the clinical and cost effectiveness of botulinum toxin type A plus an upper limb therapy programme in the treatment of post stroke upper limb spasticity. Trial design : A multi-centre open label parallel group randomised controlled trial and economic evaluation. Participants : Adults with upper limb spasticity at the shoulder, elbow, wrist or hand and reduced upper limb function due to stroke more than 1 month previously. Interventions : Botulinum toxin type A plus upper limb therapy (intervention group) or upper limb therapy alone (control group). Outcomes : Outcome assessments are undertaken at 1, 3 and 12 months. The primary outcome is upper limb function one month after study entry measured by the Action Research Arm Test (ARAT). Secondary outcomes include: spasticity (Modified Ashworth Scale); grip strength; dexterity (Nine Hole Peg Test); disability (Barthel Activities of Daily Living Index); quality of life (Stroke Impact Scale, Euroqol EQ-5D) and attainment of patient-selected goals (Canadian Occupational Performance Measure). Health and social services resource use, adverse events, use of other antispasticity treatments and patient views on the treatment will be compared. Participants are clinically reassessed at 3, 6 and 9 months to determine the need for repeat botulinum toxin type A and/or therapy. Randomisation : A web based central independent randomisation service. Blinding : Outcome assessments are undertaken by an assessor who is blinded to the randomisation group. Sample size : 332 participants provide 80% power to detect a 15% difference in treatment successes between intervention and control groups. Treatment success is defined as improvement of 3 points for those with a baseline ARAT of 0–3 and 6 points for those with ARAT of 4–56. ISRCTN78533119 EudraCT 2004-002427-40 CTA 17136/0230/001 National Institute for Health Research, Health Technology Assessment Programme. Ipsen Ltd provide botulinum toxin type A (Dysport®).
- 23 October 2008
- Published by Springer Nature in Trials
- Vol. 9 (1) , 59
Open AccessStudy design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A
Following a stroke, 55–75% of patients experience upper limb problems in the longer term. Upper limb spasticity may cause pain, deformity and reduced function, affecting mood and independence. Botulinum toxin is used increasingly to treat focal spasticity, but its impact on upper limb function after stroke is unclear. The aim of this study is to evaluate the clinical and cost effectiveness of botulinum toxin type A plus an upper limb therapy programme in the treatment of post stroke upper limb spasticity. Trial design : A multi-centre open label parallel group randomised controlled trial and economic evaluation. Participants : Adults with upper limb spasticity at the shoulder, elbow, wrist or hand and reduced upper limb function due to stroke more than 1 month previously. Interventions : Botulinum toxin type A plus upper limb therapy (intervention group) or upper limb therapy alone (control group). Outcomes : Outcome assessments are undertaken at 1, 3 and 12 months. The primary outcome is upper limb function one month after study entry measured by the Action Research Arm Test (ARAT). Secondary outcomes include: spasticity (Modified Ashworth Scale); grip strength; dexterity (Nine Hole Peg Test); disability (Barthel Activities of Daily Living Index); quality of life (Stroke Impact Scale, Euroqol EQ-5D) and attainment of patient-selected goals (Canadian Occupational Performance Measure). Health and social services resource use, adverse events, use of other antispasticity treatments and patient views on the treatment will be compared. Participants are clinically reassessed at 3, 6 and 9 months to determine the need for repeat botulinum toxin type A and/or therapy. Randomisation : A web based central independent randomisation service. Blinding : Outcome assessments are undertaken by an assessor who is blinded to the randomisation group. Sample size : 332 participants provide 80% power to detect a 15% difference in treatment successes between intervention and control groups. Treatment success is defined as improvement of 3 points for those with a baseline ARAT of 0–3 and 6 points for those with ARAT of 4–56. ISRCTN78533119 EudraCT 2004-002427-40 CTA 17136/0230/001 National Institute for Health Research, Health Technology Assessment Programme. Ipsen Ltd provide botulinum toxin type A (Dysport®).
- 1 January 2008
- Published by Taylor & Francis in Developmental Neurorehabilitation
- Vol. 11 (4) , 287
Book review
- 1 January 2008
- Published by Taylor & Francis in Developmental Neurorehabilitation
- Vol. 11 (4) , 287
Book review
- 23 March 2006
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (5) , 607-615
Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
(2006). Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy: Vol. 7, No. 5, pp. 607-615. doi: 10.1517/14656566.7.5.607
- 23 March 2006
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (5) , 607-615
Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
(2006). Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy: Vol. 7, No. 5, pp. 607-615. doi: 10.1517/14656566.7.5.607
- 30 November 2005
- Published by Wiley in European Journal of Neurology
- Vol. 12 (12) , 947-955
The use of botulinum toxin type‐B in the treatment of patients who have become unresponsive to botulinum toxin type‐A – initial experiences
The increasing use of botulinum toxin type‐A, especially for focal dystonia and spasticity has highlighted the issue of secondary non‐responsiveness. Within the last few years botulinum toxin type‐B (Myobloc®/Neurobloc®) has become commercially available as an alternative to type‐A. This paper discusses our initial experience of botulinum toxin type‐B in a total of 63 individuals who attended our botulinum clinic. Thirty‐six patients had cervical dystonia and a secondary non‐response to type‐A toxin. Thirteen of these patients (36%) had a reasonable clinical response to Neurobloc® and continue to have injections. The other 23 patients either had no response, or a poor response, or had unacceptable side effects and ceased treatment. A small number of people with blepharospasm, hemifacial spasm and foot dystonia also had a disappointing response to injection. Twenty patients with spasticity were also type‐A resistant. Seven of these show some continuing response to type‐B, without unacceptable side effects. These findings demonstrate that botulinum toxin type‐B has a place in the management of patients who have become non‐responsive to type‐A, but overall the responses to type‐B toxin were disappointing.
- 30 November 2005
- Published by Wiley in European Journal of Neurology
- Vol. 12 (12) , 947-955
The use of botulinum toxin type‐B in the treatment of patients who have become unresponsive to botulinum toxin type‐A – initial experiences
The increasing use of botulinum toxin type‐A, especially for focal dystonia and spasticity has highlighted the issue of secondary non‐responsiveness. Within the last few years botulinum toxin type‐B (Myobloc®/Neurobloc®) has become commercially available as an alternative to type‐A. This paper discusses our initial experience of botulinum toxin type‐B in a total of 63 individuals who attended our botulinum clinic. Thirty‐six patients had cervical dystonia and a secondary non‐response to type‐A toxin. Thirteen of these patients (36%) had a reasonable clinical response to Neurobloc® and continue to have injections. The other 23 patients either had no response, or a poor response, or had unacceptable side effects and ceased treatment. A small number of people with blepharospasm, hemifacial spasm and foot dystonia also had a disappointing response to injection. Twenty patients with spasticity were also type‐A resistant. Seven of these show some continuing response to type‐B, without unacceptable side effects. These findings demonstrate that botulinum toxin type‐B has a place in the management of patients who have become non‐responsive to type‐A, but overall the responses to type‐B toxin were disappointing.
- 1 December 2003
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 74 (90004) , 3iv-7
Principles of neurological rehabilitation
- 1 December 2003
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 74 (90004) , 3iv-7
Principles of neurological rehabilitation